British Science Week runs from 8th to 17th March – a 10-day celebration of science, technology, engineering and maths (STEM), featuring entertaining and engaging events and activities across the UK for people of all ages.

If you’ve got a love of science and would like to work in an environment that positively embraces STEM, then take a closer look at our Teva Runcorn site in Cheshire, where we have a large manufacturing facility as well as two teams of research and development scientists. 

Teva Runcorn signed up to the STEM Ambassador programme in 2017 to support the professional development of its current, highly skilled workforce. It also helps the business reach out to communities and educational institutions to support and encourage the next generations of STEM students and employees. 

Teva Runcorn specialises in difficult-to-make medicines which means the site is teeming with bright and ambitious professionals who are passionate about what they do. A recruitment drive is now underway to find highly educated STEM candidates who can be further developed and trained in-house.

Teva Runcorn employs around 500 colleagues, working in a variety of roles, ranging from quality assurance, manufacturing operations, research and development, engineering, microbiology and packaging.

Claire d’Abreu-Hayling, Senior Vice President, Global Sterile R&D, said:

"What we feel makes us unique is the depth of talent within our organisation; every single person is degree educated and highly skilled in their chosen field.
With a high-quality workforce, our company can develop increasingly higher-tech products, both in terms of medicines and devices and compete in the world market in innovation, research and increased complexity."

Teva Runcorn develops a range of sterile pharmaceutical products for respiratory conditions, such as nebulisation medicines which help people suffering from asthma or Chronic Obstructive Pulmonary Disease (COPD), and tobramycin which is used in the treatment of Cystic Fibrosis patients. It also manufactures ophthalmological medicines used in the treatment of glaucoma and chronic dry eye conditions. 

The team manufactures Pre-filled Syringe (PFS) medicines such as Teva’s innovative medicine Copaxone® (glatiramer acetate). Copaxone® is used to treat multiple sclerosis (MS) a condition affecting the central nervous system. 

Runcorn is also home to two R&D centres developing sterile drug products and sterile device technology and the Sterile Training Academy – a centre of excellence within Teva for sterile manufacturing, safety and compliance training.

We're proud of our employees at Teva Runcorn and every single one of them makes a valuable contribution to fulfilling our purpose of improving health and making people feel better. But don’t just take our word for it, see what our colleagues have to say in their own words: Colleagues in roles such as new product development, operations, engineering and compliance share their experience of working at Teva on our website.

Teva provides medicines to 200 million people around the world every day.1 In the UK we supply more medicines to the NHS than anyone else.2 We combine the strengths of the world’s top generics company with excellence in specialty medicine development, and we focus on making better days for patients all around the world.

For more information about British Science Week, go to



[1] Teva Pharmaceutical Industries - Data on file
[2] Teva UK Limited – Data on file

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. Learn more at

Date of preparation: March 2019
Ref: UK/CPE/19/0003